Gene · 9045
RPL14: ribosomal protein L14
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL14: ribosomal protein L14. Genes, record 9045. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9045
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P50914 | Large ribosomal subunit protein eL14 | 215 | 176 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 11365 | P50914 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6949 | P50914 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 6949 | P50914 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11365 | P50914 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5677 | P50914 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 6937 | P50914 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73947 | P50914 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73948 | P50914 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176918 | P50914 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176919 | P50914 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants542
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL14 papers | Newest fiscal year |
|---|---|---|---|
| P30CA068485 | Cancer Center Support Grant | 6 | 2025 |
| R01CA200709 | Facilitated recruitment of MYC to chromatin by interaction with WDR5 | 6 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 4 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 4 | 2025 |
| T32CA119925 | Integrated Biological Systems Training in Oncology | 4 | 2025 |
| P50CA236733 | Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer | 3 | 2025 |
| T32CA217834 | VOLT (Vanderbilt Oncology Training Program) | 3 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 542Source NIH's project files
See all 542 nih grantsPapers808
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Plasma proteome-genome integration reveals novel protein biomarkers and therapeutic targets linked to breast cancer survival. | Arch Med Sci | 2026 | 42540540 | PubTator, text mining | PubMed |
| The Helicobacter pylori ribosomal silencing factor RsfS is required for low-growth states and chronic infection. | bioRxiv | 2026 | 41929121 | PubTator, text mining | PubMed |
| Nucleolus as a cornerstone linking proliferation and metabolism to cellular responses to stress: involvement of transcription factors MYC and p53. | Front Mol Biosci | 2026 | 41777667 | PubTator, text mining | PubMed |
| RNAseq-based meta-analyses revealed tumor suppressor-inducer fusion events in liver, oral, and ovarian cancer in the Indian population: a cancer cell surviving mechanism. | Nucleosides Nucleotides Nucleic Acids | 2026 | 41661231 | PubTator, text mining | PubMed |
| Lactylation Plays a Novel Role in the Tumor Microenvironment and its Prognostic Implications for Breast Cancer. | Recent Pat Anticancer Drug Discov | 2026 | 41582583 | PubTator, text mining | PubMed |
| Design and in-silico evaluation of PNA-based novel pronucleotide analogues targeting RNA-dependent RNA polymerase to combat COVID-19. | J Biomol Struct Dyn | 2026 | 39937582 | PubTator, text mining | PubMed |
| Gene Regulation in Comorbid Migraine and Myogenic Temporomandibular Disorder Pain. | Genes (Basel) | 2025 | 41465107 | PubTator, text mining | PubMed |
| Extracellular vesicles for macrophage reprogramming: an emerging paradigm in immunomodulatory therapeutics. | J Biol Eng | 2025 | 41430279 | PubTator, text mining | PubMed |
| Decoding immune-metabolic crosstalk in ARDS: a transcriptomic exploration of biomarkers, cellular dynamics, and therapeutic pathways. | Front Immunol | 2025 | 41221285 | PubTator, text mining | PubMed |
| LTO1 and YAE1 regulate MHC-I expression via nonsense-mediated RNA decay in tumor cells. | J Immunother Cancer | 2025 | 40987494 | PubTator, text mining | PubMed |
1 to 10 of 808
See all 808 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9045
GET https://conductscience.org/api/genes/v1/9045/patents?page=2